New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives.

Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulm Med (2015) 0.86

Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.81

Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis (2016) 0.79

Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life. Int J Chron Obstruct Pulmon Dis (2015) 0.77

Drugs for chronic obstructive pulmonary disease. Aust Prescr (2017) 0.75

Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management. Adv Ther (2016) 0.75

Randomized, double-blind, placebo-controlled superiority trial of the Yiqigubiao pill for the treatment of patients with chronic obstructive pulmonary disease at a stable stage. Exp Ther Med (2016) 0.75

Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations. Pharmacoeconomics (2017) 0.75

Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study. Int J Chron Obstruct Pulmon Dis (2017) 0.75

Pharmacological treatment for COPD; GOLD 2017 changes direction. Br J Clin Pharmacol (2017) 0.75

Optimum treatment for chronic obstructive pulmonary disease exacerbation prevention. Ann Transl Med (2016) 0.75

Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2016) 0.75

Eligibility of real-life patients with COPD for inclusion in RCTs: a commentary. Respir Res (2017) 0.75

When is dual bronchodilation indicated in COPD? Int J Chron Obstruct Pulmon Dis (2017) 0.75

Small Airway Disease in Patients with Chronic Obstructive Pulmonary Disease. Tuberc Respir Dis (Seoul) (2017) 0.75

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med (2007) 19.86

A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med (2008) 17.19

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med (2007) 8.06

Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med (2011) 6.56

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med (2007) 5.51

Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet (2009) 5.51

The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest (1984) 5.19

Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J (2013) 4.65

Chronic obstructive pulmonary disease. Lancet (2012) 4.43

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med (2013) 4.22

Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax (2003) 3.62

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med (2012) 3.51

Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest (2004) 3.38

Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med (2013) 3.05

Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest (2006) 3.01

Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med (2013) 2.75

Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J (2005) 2.60

Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med (2014) 2.48

Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol (1991) 2.41

Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med (2014) 2.00

Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J (2003) 1.84

Pharmacology and therapeutics of bronchodilators. Pharmacol Rev (2012) 1.72

Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med (2008) 1.55

Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest (2014) 1.47

Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance. BMJ (2010) 1.43

QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax (2010) 1.36

Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J (2013) 1.33

Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs (2005) 1.33

The MCID of the transition dyspnea index is a total score of one unit. COPD (2005) 1.32

Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD (2009) 1.30

Measuring bronchodilation in COPD clinical trials. Br J Clin Pharmacol (2005) 1.24

Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. Respir Med (2010) 1.23

A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med (2008) 1.21

Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. Respir Res (2011) 1.19

Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med (2013) 1.19

Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res (2014) 1.11

Small airway obstruction in COPD: new insights based on micro-CT imaging and MRI imaging. Chest (2013) 1.09

Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir Med (2009) 1.07

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J Chron Obstruct Pulmon Dis (2013) 1.05

Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med (2008) 1.03

Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. Drugs (2009) 1.03

Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches. Respir Res (2011) 1.01

Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther (2009) 1.01

Efficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic review. Chest (2014) 0.97

Real-life use of fluticasone propionate/salmeterol in patients with chronic obstructive pulmonary disease: a French observational study. BMC Pulm Med (2014) 0.95

A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients. Pulm Pharmacol Ther (2012) 0.89

Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Respir Med (2008) 0.86

New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. Drug Des Devel Ther (2013) 0.85